ERBB2 and breast carcinoma: An important observation was that the growth in vitro and in vivo of more aggressive breast cancer subtypes such as HER2+ breast cancer and TNBC, and of lapatinib-refractory (HER2 small molecule inhibitor-refractory) tumors was slowed by HER3-VIA.